1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Novo Nordisk Shows It Is Ready To Extend Its Obesity Portfolio

Novel Oral Obesity Drug Shows Promise

 
• By Jessica Merrill

During a capital markets day, the company highlighted Phase I weight loss data for its novel oral obesity drug amycretin, which could work in a complementary fashion to GLP-1s. 

scale
Novo Nordisk revealed new obesity drug data • Source: Shutterstock

Novo Nordisk A/S revealed encouraging efficacy data for a novel oral obesity medicine during a capital market day on 7 March, intriguing investors who are aware the company will need to deliver next-generation advances in obesity to maintain its leadership position in the competitive therapeutic area.

Key Takeaways
  • Novo Nordisk revealed encouraging efficacy data for a novel oral obesity medicine amycretin during a capital market day.

Amycretin, which is a co-agonist of the GLP-1 and amylin receptors, could be a complementary mode of action to Novo...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: EU tariff deal leaves questions for pharma; Prasad’s CBER exit could bode well for genetic medicines; Winrevair grows but Merck & Co. plans cost cuts; Novo Nordisk selects new CEO; and a look at obesity past the GLP-1s.

Metabolic Disease-Focused Poxel Teeters On The Edge

 
• By Andrew McConaghie

The Lyon, France-based company has filed for insolvency and is running out of time to find new funding for its metabolic disease pipeline.

Novo Selects Internal CEO To Recharge Growth

 
• By Jessica Merrill

Maziar Mike Doustdar has led the company’s international operations and will succeed Lars Fruergaard Jørgensen on August 7.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By Joseph Haas

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

More from Therapy Areas

BioNTech Outlines Development Plan For PD-L1xVEGF-Targeting BNT-327

 
• By Jessica Merrill

The company, with partner Bristol Myers Squibb, has a three-wave development strategy for BNT-327: “establish, combine, broaden.”

AstraZeneca’s Tagrisso Mountain Grows, But The Climb Will Be Challenging

 
• By Aakash Babu

The UK major continues to post promising data readouts that further emphasize the safety and efficacy of its blockbuster lung cancer drug, but competition from J&J's Rybrevant is ramping up, and capable challengers are emerging.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: EU tariff deal leaves questions for pharma; Prasad’s CBER exit could bode well for genetic medicines; Winrevair grows but Merck & Co. plans cost cuts; Novo Nordisk selects new CEO; and a look at obesity past the GLP-1s.